J&J files U.S. applications for expanded use of IV golimumab

Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies has filed two supplemental marketing applications in the U.S. seeking approval to use Simponi Aria (golimumab) to treat polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in patients at least two years old (in combination with methotrexate).

Simponi Aria is an intravenously administered formulation of Simponi (administered via subcutaneous injection).

https://seekingalpha.com/news/3564182-j-and-j-files-u-s-applications-for-expanded-use-of-iv-golimumab